Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all‐oral direct acting antivirals in patients with chronic hepatitis C virus infection. Issue 5 (7th February 2019)

• Record Type: Journal Article
• Authors: Nakashima, Megumi; Toyoda, Hidenori; Tada, Toshifumi; Mizuno, Kazuyuki; Iio, Etsuko; Tanaka, Yasuhito; Sugiyama, Tadashi; Yoshimura, Tomoaki; Kumada, Takashi
• Is Part Of: Hepatology research. Volume 49:Issue 5(2019)
• Page Start: 512
• Page End: 520
• Publication Date: 2019-02-07
• Subjects: anemia -- chronic hepatitis C -- direct‐acting antiviral agent -- renal dysfunction -- ribavirin; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.13311
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: Several interferon (IFN)‐free, all‐oral regimens with direct acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection also include ribavirin (RBV). We investigated the influence of renal dysfunction on virologic efficacy and adverse effects in 189 patients with HCV genotype 2 infection who received combination RBV–DAA regimens. Methods: The incidence of RBV‐induced anemia, RBV dose reduction, and virologic efficacy were compared according to baseline renal function as defined by the estimated glomerular filtration rate (eGFR). Results: Patients with renal dysfunction (eGFR = 30–59 mL/min/1.73 m 2 ) had higher rate of RBV dose reduction and more marked decreases in hemoglobin levels. These findings were more pronounced in patients with the ITPA CC genotype, who are more sensitive to RBV‐induced anemia. Although there were no statistically significant differences in sustained virologic response (SVR) rates according to renal function overall ( P = 0.1650), the SVR rate was significantly lower in patients who required RBV dose reduction than in those who did not ( P < 0.0001). Conclusions: Baseline renal dysfunction could unfavorably affect the outcomes of RBV–DAA in patients with chronic HCV infection due to the increased risk of RBV dose reduction, even in the era of IFN‐free DAA regimens.